bluebird bio (BLUE) Stock Price, News & Analysis

Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Key Stats

• Today's Range: $4.97 to $4.97
• 50-Day Range: $3.29 to $5.00
• 52-Week Range: $3.20 to $25.10
• Volume: N/A
• Average Volume: 452,966 shs
• Market Capitalization: $48.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.75
• Consensus Rating: Hold

bluebird bio Stock Analysis - MarketRank™

bluebird bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 716th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

bluebird bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for bluebird bio are expected to grow in the coming year, from ($27.25) to ($11.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

bluebird bio has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BLUE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bluebird bio does not currently pay a dividend.

Dividend Growth

bluebird bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BLUE.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added bluebird bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bluebird bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of bluebird bio is held by insiders.

Percentage Held by Institutions

87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BLUE Stock Analysis - Frequently Asked Questions

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($13.80) by $0.60. bluebird bio's quarterly revenue was up 17364.8% on a year-over-year basis.
Read the conference call transcript.

When did bluebird bio's stock split?

bluebird bio shares reverse split before market open on Friday, December 13th 2024.The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are bluebird bio's major shareholders?

Top institutional investors of bluebird bio include Jane Street Group LLC, Equitec Proprietary Markets LLC and FNY Investment Advisers LLC. Insiders that own company stock include Andrew Obenshain, Nick Leschly, Jason Cole, Thomas J Klima, Richard A Colvin and Christopher Krawtschuk.
View institutional ownership trends.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 11/07/2023
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLUE
• CIK: 1293971
• Web: www.bluebirdbio.com
• Phone: (339) 499-9300
• Fax: N/A
• Employees: 520
• Year Founded: N/A

Price Target and Rating

• Average Price Target for bluebird bio: $44.60
• High Price Target: $120.00
• Low Price Target: $5.00
• Potential Upside/Downside: +797.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($41.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$211.91 million
• Net Margins: -565.74%
• Pretax Margin: -551.41%
• Return on Equity: -322.46%
• Return on Assets: -53.17%

Debt

• Debt-to-Equity Ratio: 0.37
• Current Ratio: 0.51
• Quick Ratio: 0.33

Sales & Book Value

• Annual Sales: $103.95 million
• Price / Sales: 0.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $35.59 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 9,792,000
• Free Float: 9,586,000
• Market Cap: $48.67 million
• Optionable: Optionable
• Beta: 0.27